Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.35 |
| ▸ | FPR2 | P25090 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12569462 | 0.80 | PIM1 (0.39) | APPPIM1NNMTSCN9AFPR2 | |
| SCHEMBL25093421 | 0.79 | BRD4 (0.42) | EIF4A3SCN9ATLR8TLR7 | |
| SCHEMBL27398487 | 0.78 | KMT2A (0.42) | PIM1NNMTSCN9AFPR2KMT2A | |
| SCHEMBL25093457 | 0.77 | NPC1 (0.45) | — | |
| SCHEMBL22768560 | 0.76 | NNMT (0.46) | APPPIM1NNMT | |
| SCHEMBL18488030 | 0.75 | SYK (0.43) | APPPIM1NNMTSCN9AFPR2 | |
| SCHEMBL16751982 | 0.72 | APP (0.42) | APPPIM1NNMTSCN9AKMT2A | |
| SCHEMBL26898632 | 0.71 | EIF4A3 (0.36) | EIF4A3KMT2A | |
| SCHEMBL84353 | 0.71 | NOS2 (0.37) | — | |
| SCHEMBL4734695 | 0.70 | EIF4A3 (0.32) | EIF4A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | APP 1550/4885PIM1 4235/4885NNMT 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.